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Pharmacological thromboprophylaxis reduces the risk of symptomatic venous thromboembolism 
(VTE) in people with lower limb immobilisation due to injury (Zee et al, 2017) but can increase the risk 
of bleeding. Clinicians therefore need to weigh the risks and benefits of thromboprophylaxis to 
determine the overall benefit of treatment. Decision-analytic modelling can inform this process by 
simulating patient management according to alternative strategies to determine the probability of 
different outcomes with each strategy. Outcomes can then be valued as quality-adjusted life years 
(QALYs) to determine which strategy is associated with the greatest quality-adjusted life expectancy. 
We developed a decision-analytic model to compare the management of a cohort of patients with 
lower limb immobilisation following injury receiving pharmacological thromboprophylaxis to 
management without this treatment, in terms of 6-month and 5-year outcomes, and lifetime QALYs.  
Full details of the methods and data sources are provided in the online appendix. Briefly, a six-month 
decision tree model was used to estimate for each strategy; the number of patients receiving 
thromboprophylaxis, the impact of thromboprophylaxis on VTE outcomes (pulmonary emboli (PE) and 
deep vein thrombosis (DVT)), and the incidence of major bleeds during either thromboprophylaxis or 
VTE treatment with anticoagulants. Major bleeds were divided into fatal bleeds, non-fatal intracranial 
haemorrhage (ICH) and other major bleeds. PEs were divided into fatal and non-fatal events. DVTs 
were divided first into symptomatic and asymptomatic DVTs and then into proximal and distal DVTs. 
Symptomatic DVTs and non-fatal PEs are assumed to result in 3 months of anticoagulant treatment. 
A Markov model was then used to extrapolate life-time outcomes including overall survival and 
ongoing morbidity related to either bleeds or VTE. The health states included within the Markov model 
capture the risk of post-thrombotic syndrome (PTS) following VTE and the risk of chronic 
thromboembolic pulmonary hypertension (CTEPH) following PE. The risk of PTS is dependent on 
whether the DVT is symptomatic and treated or asymptomatic and untreated and also whether the 
DVT is proximal or distal. The CTEPH state is divided according to whether patients receive medical or 
surgical management to allow for differential costs and survival between these groups. There is also 
a post ICH state to capture ongoing morbidity following ICHs. 
The effectiveness of thromboprophylaxis and the risk of VTE in patients not receiving 
thromboprophylaxis were estimated from a systematic review of thromboprophylaxis in lower limb 
immobilisation (Pandor et al, in press). The relative risk of bleeding was estimated from a systematic 
review of thromboprophylaxis across multiple conditions (National Clinical Guideline Centre  ? Acute 
and Chronic Conditions (UK), 2010) and applied to a baseline risk of bleeding from a large primary care 
database with 16.4 million person years of follow-up (Hippisley-Cox and Coupland 2014). The data 
sources used to determine the probabilites of subsequent events in the decision tree and Markov 
models are described in the online appendix. 
QALYs were estimated by applying estimates of health utility (a measure of health-related quality of 
life on a scale of zero to one) to life expectancy after each of the events in the model. During the 
decision tree phase, absolute utility values were applied based on the events occurring, with age 
dependent general population values applied to those not having any events. A disutility (i.e. a 
reduction in quality of life) was applied to patients receiving prophylaxis with LMWH to account for 
the impact of regular injections and a disutility was ĂƉƉůŝĞĚĚƵƌŝŶŐsdƚƌĞĂƚŵĞŶƚƚŽƌĞĨůĞĐƚƉĂƚŝĞŶƚƐ ?
preferences to avoid long-term treatment. During the Markov model phase, patients without long-
term sequelae or ongoing symptoms have general population levels of utility which vary with age and 
those with sequelae or ongoing symptoms have utility multipliers applied which reduce their utility by 
a fixed proportion relative to the general population level for their age. Details of utilities and life 
expectancy after each of the model states are provided in the online appendix. 
Short and long-term clinical outcomes per 100,000 patients are presented in Table 1. The model 
predicts that the combined rate of serious acute adverse outcomes (ICH or death from VTE or 
bleeding) would be very low regardless of whether thromboprophylaxis is used (around 1 in 4000). 
The short-term benefits of thromboprophylaxis lie in reducing the rates of non-fatal PE (225 versus 
415 per 100,000), symptomatic DVT (492 versus 907 per 100,000) and asymptomatic DVT (3820 versus 
7052 per 100,000). These lead to longer term benefits in terms of reduced risks of PTS (1007 versus 
1859 per 100,000) and CTEPH (6 versus 11 per 100,000), with an additional 4 patients in 100,000 
surviving to 5 years compared with no thromboprophylaxis. Overall, thromboprophylaxis is estimated 
to result in 0.015 additional QALYs per patient (95% credible interval [CrI] 0.004 to 0.029). 
Our findings suggest that thromboprophylaxis increases quality-adjusted life expectancy for people 
with lower limb immobilisation due to injury, but this is driven by the prevention of long-term 
complications, particularly the utility loss attributed to PTS and the prevention of PTS in patients with 
asymptomatic DVT, rather than the risk of short-term adverse outcomes. This may be at odds with the 
commonly perceived rationale for providing thromboprophylaxis. The effect of thromboprophylaxis 
upon PTS is based on a number of assumptions and extrapolations, rather than direct evidence, so 
further research is required to determine whether this potential benefit is realised in practice. 
The estimates of adverse outcomes provided by our analysis can be used by clinicians to advise 
patients on the risks and benefits of thromboprophylaxis and support shared decision-making. 
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Table 1: Predicted clinical outcomes per 100,000 patients with lower limb immobilisation due to injury 
 Outcomes at 6 months per 100,000 patients  Outcomes at 5 years per 100,000 patients 
  Fatal 
PE 
Fatal 
bleed 
Non-
fatal 
ICH 
Other 
major 
bleeda 
Non-
fatal 
PE 
Symptomatic 
DVT 
Asymptomatic 
DVT 
PTS  PE 
survivor 
with 
CTEPH 
PE 
survivor 
without 
CTEPH 
ICH 
survivor 
Dead 
(any 
cause) 
No 
prophylaxis 12 9 5 26 415 907 7052 1859 11 397 5 1133 
Prophylaxis 7 12 8 35 225 492 3820 1007 6 215 7 1129 
Abbreviations: CTEPH, chronic thromboembolic pulmonary hypertension, DVT, deep vein thrombosis; ICH, intracranial haemorrhage, PE, 
pulmonary embolism; PTS, post-thrombotic syndrome. 
a Patients having other major bleeds could also have a DVT or non-fatal PE 
 
